SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Millennium Pharmaceuticals, Inc. (MLNM)
An SI Board Since February 1997
Posts SubjectMarks Bans Symbol
3044 135 0 MLNM
Emcee:  icanpickem Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
2894Millennium Initiates Phase III Trial to Determine the Optimal VELCADE(R) (BortezIcebrg-7/16/2007
2893Shrink Your Tumor… Or Your Money Back! siliconinvestor.comDewDiligence_on_SI-7/14/2007
2892[Antitumor Activity of PR-171, a Novel Irreversible Inhibitor of the Proteasome]tuck-7/11/2007
2891TRAIL therapy in non-small cell lung cancer cells: sensitization to death receptIcebrg-7/11/2007
2890Single agent bortezomib in the treatment of relapsed and refractory Hodgkin lympIcebrg-7/10/2007
2889Bortezomib in combination with intermediate-dose dexamethasone and continuous loIcebrg-7/10/2007
2888[Efficacy of single-agent bortezomib vs. single-agent thalidomide in patients wituck-7/5/2007
2887VELCADE(R) (bortezomib) for Injection Based Induction Therapy Delivered High PosIcebrg-7/4/2007
2886[Biotech Mailbag: Adam Feuerstein gives his opinion on Millennium and the companIcebrg-6/30/2007
2885The best is yet to be [Boronate] 29-Jun-07 11:02 am The frontline reIcebrg-6/29/2007
2884Susquehanna on MLNM's Velcade Data at Kos Millennium Pharmaceuticals, Inc. Icebrg-6/29/2007
2883Emerging data on the use of anthracyclines in combination with bortezomib in mulIcebrg-6/29/2007
2882Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety PrIcebrg-6/29/2007
2881VELCADE(R) (Bortezomib) for Injection Addressed Disease-Related Complications AsIcebrg-6/28/2007
2880VELCADE(R) (Bortezomib) for Injection Based Therapies Produced Complete RemissioIcebrg-6/28/2007
2879VELCADE(R) (Bortezomib) for Injection Based Therapies Achieved Survival Rates asIcebrg-6/28/2007
2878Millenium Pharmaceuticals A Sell On Strong Competition, Slowed Growth Posted onIcebrg-6/28/2007
2877Millennium Upgraded As Analyst Expects Better Velcade Sales NEW YORK (AP) -- MiIcebrg-6/28/2007
2876Incorporating bortezomib into upfront treatment for multiple myeloma: early resuIcebrg-6/27/2007
2875[Carfilzomib against pre-clinical models of multiple myeloma] >>Blood. 20tuck-6/27/2007
2874Upstaging Velcade [Source: BioCentury] By Alexei Ku Staff Writer When MillenniIcebrg-6/22/2007
2873Have read that final guidance from NICE on this issue is expected this October. tuck-6/22/2007
28725-Azacytidine, a DNA methyltransferase inhibitor, induces ATR-mediated DNA doublIcebrg-6/21/2007
2871A parallel dose-escalation study of weekly and twice-weekly bortezomib in combinIcebrg-6/21/2007
2870Weekly Docetaxel and Bortezomib as First-Line Treatment for Patients with HormonIcebrg-6/8/2007
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News